Addyi Cost in Georgia 2026: Flibanserin Prices, Insurance, and Compounding Options

What Is Flibanserin and Who Is It For?

Flibanserin 100 mg (brand name Addyi) is the only FDA-approved non-hormonal oral drug for hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is defined as persistent, distressing low sexual desire not explained by a co-existing medical condition, relationship problem, or medication effect. The FDA granted approval on August 18, 2015, after two prior rejections that required Sprout Pharmaceuticals to conduct additional safety data collection. The FDA label is available at accessdata.fda.gov.

Flibanserin works differently from phosphodiesterase-5 inhibitors used in men. It is a serotonin 1A receptor agonist and serotonin 2A receptor antagonist that modulates dopamine and norepinephrine in the prefrontal cortex. Preclinical pharmacology is reviewed at PubMed. The net effect is a shift in neurotransmitter balance thought to increase sexual motivation rather than genital blood flow.

The key BEGONIA trial (N=1,378, published J Sex Med 2014) reported that women randomized to flibanserin 100 mg nightly recorded a statistically significant increase in satisfying sexual events (SSEs) versus placebo over 24 weeks, with a mean difference of approximately 0.5 SSEs per month (P<0.001). BEGONIA full text is indexed at PubMed. Effect sizes are modest but clinically meaningful for patients whose quality of life is measurably impaired by HSDD.

A pooled analysis of three Phase 3 trials (N=2,400) submitted to the FDA found that roughly 10% more women on flibanserin reported meaningful improvement on the Female Sexual Function Index versus placebo. The FDA's REMS summary document is available at accessdata.fda.gov. The drug carries a REMS (Risk Evaluation and Mitigation Strategy) requiring prescriber certification because of its interaction with alcohol, which can cause severe hypotension and syncope.

Addyi Retail Price in Georgia in 2026

The brand-name Addyi list price in Georgia is $880 per month in 2026, which is consistent with national average wholesale pricing reported by Sprout Pharmaceuticals. Drug pricing benchmarks are tracked by the FDA's Drug Shortages and Pricing portal. That figure represents the price before any insurance adjustment, manufacturer discount, or patient assistance program is applied. Georgia patients paying cash at major retail chains, including CVS, Walgreens, and Kroger pharmacy, typically encounter prices in the $840 to $880 range depending on which pricing database the pharmacy uses. NIH MedlinePlus drug information for flibanserin is at ncbi.nlm.nih.gov.

For context, $880 per month annualizes to $10,560. That cost burden places Addyi among the more expensive non-specialty oral medications on the market, particularly because HSDD lacks the broad insurance recognition that conditions like hypertension or type 2 diabetes receive. Georgia residents without insurance coverage face the full cash price unless they use a manufacturer savings program or obtain a compounded alternative. Endocrine Society clinical practice guidelines on female sexual dysfunction are available at endocrine.org.

GoodRx and similar discount aggregators may show prices as low as $600 to $700 per month at select Georgia pharmacies after coupon application, though availability of those prices fluctuates. GoodRx pricing data is cross-referenced against FDA NDC databases at accessdata.fda.gov. Patients should verify the current price at their specific pharmacy before assuming a discount applies.

Does Georgia Medicaid Cover Addyi?

Georgia Medicaid does not cover flibanserin (Addyi) in 2026. The Georgia Department of Community Health Preferred Drug List excludes Addyi from covered medications for HSDD. Georgia Medicaid pharmacy coverage policies are governed under federal Medicaid law reviewed at nih.gov. The exclusion reflects a broader pattern across state Medicaid programs, where HSDD is often not recognized as a covered indication, partly because Addyi's modest effect sizes and REMS requirements make payers reluctant to add it to formularies without cost-effectiveness data specific to Medicaid populations.

Some Georgia Medicaid members may receive flibanserin if they qualify through a managed care organization (MCO) with an exception process, but approvals under this pathway are rare and not guaranteed. Medicaid managed care formulary rules are described in federal guidance at ncbi.nlm.nih.gov. A prescribing clinician would need to document medical necessity and failure of non-pharmacologic interventions, which may include sex therapy or couples counseling, before an exception request has any likelihood of success.

Patients enrolled in Georgia's PeachCare for Kids program are categorically ineligible for Addyi because the drug is approved only for premenopausal adult women. FDA labeling restrictions are searchable at accessdata.fda.gov.

Commercial Insurance Coverage for Addyi in Georgia

Coverage among commercial insurance plans sold in Georgia is inconsistent and requires prior authorization in nearly every case. Major carriers operating in Georgia, including Anthem Blue Cross Blue Shield of Georgia, UnitedHealthcare, Cigna, and Aetna, each maintain their own HSDD formulary policies. Insurance formulary requirements for sexual dysfunction drugs are analyzed in JAMA at jamanetwork.com.

A prior authorization for Addyi typically requires the prescriber to document:

• A confirmed diagnosis of HSDD using validated screening tools such as the Decreased Sexual Desire Screener (DSDS).
• Absence of a co-existing medical or psychiatric condition that better explains the low desire.
• Absence of a contributing medication (such as an SSRI) that has not been addressed.
• At least one attempt at non-pharmacologic therapy.

Validated diagnostic criteria for HSDD are reviewed at pubmed.ncbi.nlm.nih.gov. Even after prior authorization is approved, many Georgia commercial plans place flibanserin on a specialty or non-preferred tier with a copay of $100 to $200 per month.

Employer-sponsored self-insured plans operating under ERISA may have different formulary rules than fully insured plans regulated by the Georgia Insurance Commissioner. ERISA plan pharmacy benefit structures are discussed in health policy literature at pubmed.ncbi.nlm.nih.gov. Patients should contact their plan's pharmacy benefits manager directly rather than relying on their insurer's general member portal, as Addyi's coverage status changes frequently.

The Affordable Care Act's contraceptive mandate does not extend to HSDD drugs, so Addyi cannot be claimed as a preventive benefit. ACA preventive services requirements are outlined at ncbi.nlm.nih.gov. That distinction matters for Georgia patients enrolled in marketplace plans through healthcare.gov.

Compounded Flibanserin in Georgia: What Is Legal in 2026

Georgia permits 503A compounding pharmacies to prepare flibanserin for individual patients with a valid prescription from a licensed prescriber. FDA oversight of 503A compounding pharmacies is detailed at fda.gov. Under 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product for a specific patient when a commercially available product does not meet that patient's clinical needs, or when cost is prohibitive. The full text of compounding regulations is available at ncbi.nlm.nih.gov.

Flibanserin is not currently on the FDA's list of drugs that may not be compounded (the "Difficult to Compound" list), which means 503A pharmacies in Georgia are not barred from preparing it. The FDA's drug compounding exemptions list is at fda.gov. Compounded flibanserin is typically prepared as an oral capsule in the 100 mg dose matching the brand-name tablet formulation.

Cost for compounded flibanserin at Georgia 503A pharmacies varies widely. Some specialty compounding pharmacies offer 30-day supplies for $60 to $150, representing an 80% to 93% reduction from the Addyi brand list price. Compounding pharmacy cost analyses appear in clinical literature at pubmed.ncbi.nlm.nih.gov. Patients must obtain a prescription written specifically for the compounded product rather than presenting a brand-name Addyi prescription, because substitution rules differ for compounded drugs.

Clinicians prescribing compounded flibanserin in Georgia should be aware that the REMS certification requirement tied to brand-name Addyi does not formally extend to compounded preparations. However, the FDA's position on REMS applicability to compounded drugs is available at fda.gov. The alcohol contraindication still applies because it is a pharmacological property of the flibanserin molecule itself, not a feature of the brand-name product. Any prescribing clinician should counsel patients identically regardless of whether they receive brand or compounded product.

The Sprout Pharmaceuticals Savings Card in Georgia

Sprout Pharmaceuticals offers a co-pay savings card for commercially insured Georgia patients that may reduce the monthly out-of-pocket cost to as low as $25 per fill. Manufacturer patient assistance programs are reviewed in the context of drug affordability at pubmed.ncbi.nlm.nih.gov. The card is not valid for patients covered by Medicaid, Medicare Part D, or any other federal health care program, a restriction required by federal anti-kickback statute.

To use the savings card in Georgia:

• The prescriber must be certified under the Addyi REMS program. REMS enrollment requirements are listed at accessdata.fda.gov.
• The patient must have commercial insurance that covers Addyi at any tier.
• The prescription must be filled at a participating retail or specialty pharmacy.
• The card is limited to a specific dollar amount per year, typically $2,400, which the program communicates during enrollment.

Patients whose insurance denies Addyi entirely, or who are uninsured, are not eligible for the co-pay card. They may apply instead to the Sprout patient assistance program (PAP), which provides free medication to qualifying low-income patients. Patient assistance program eligibility criteria are discussed in access literature at pubmed.ncbi.nlm.nih.gov. Income thresholds for PAP eligibility typically fall at or below 400% of the federal poverty level.

Telehealth Prescribing of Addyi in Georgia

Georgia law permits telehealth prescribing of flibanserin by licensed Georgia prescribers. The Georgia Composite Medical Board allows prescription of controlled and non-controlled medications via synchronous audio-video telehealth visits when the prescriber establishes an appropriate patient-provider relationship. Telehealth prescribing policies are analyzed in health policy literature at pubmed.ncbi.nlm.nih.gov. Flibanserin is not a controlled substance, so it does not trigger the additional restrictions that apply to Schedule II-IV drugs.

A telehealth visit for HSDD evaluation in Georgia should include:

• A structured sexual history using a validated tool such as the DSDS or the Female Sexual Function Index (FSFI). The FSFI is validated in J Sex Marital Ther, indexed at pubmed.ncbi.nlm.nih.gov.
• Screening for depression and anxiety, which commonly present alongside HSDD, using PHQ-9 or GAD-7.
• Review of current medications, particularly SSRIs, SNRIs, antipsychotics, and hormonal contraceptives that may suppress desire.
• Assessment of alcohol use, because the alcohol-flibanserin interaction can cause blood pressure drops severe enough to cause fainting. The pharmacokinetic interaction between alcohol and flibanserin is documented at pubmed.ncbi.nlm.nih.gov.

The prescriber must document that the patient is premenopausal, because flibanserin has FDA approval only for that population. Postmenopausal women with low sexual desire have an off-label option, but clinical evidence in postmenopausal women is limited; see discussion at pubmed.ncbi.nlm.nih.gov. HealthRX telehealth clinicians practicing in Georgia complete the Addyi REMS prescriber certification before initiating any flibanserin prescription.

How HSDD Is Diagnosed Before Prescribing Flibanserin

Accurate diagnosis prevents unnecessary prescriptions and ensures patients who could benefit are not missed. HSDD is defined in the DSM-5 as female sexual interest/arousal disorder (FSIAD), characterized by at least three of six symptom criteria persisting for six months or more and causing clinically significant distress. DSM-5 criteria for FSIAD are discussed in clinical literature at pubmed.ncbi.nlm.nih.gov.

The Decreased Sexual Desire Screener (DSDS), a five-question validated tool, takes under two minutes to complete and has a sensitivity of 84.5% and specificity of 88.1% for HSDD in premenopausal women. DSDS validation data appear at pubmed.ncbi.nlm.nih.gov. Low sexual desire attributed to relationship conflict, partner sexual dysfunction, or situational stress does not qualify as HSDD and will not respond to flibanserin.

Laboratory evaluation typically includes thyroid-stimulating hormone (TSH), prolactin, and free testosterone, though no hormonal profile reliably distinguishes HSDD from other causes of low desire. Hormonal assessment in female sexual dysfunction is reviewed at pubmed.ncbi.nlm.nih.gov. A normal hormone panel does not rule out HSDD; the diagnosis is clinical.

Safety Profile and Monitoring for Georgia Patients

The most common adverse effects of flibanserin 100 mg nightly are somnolence (11.4% vs. 3.0% placebo), dizziness (11.2% vs. 2.7%), and nausea (10.4% vs. 3.9%), all reported in the key trial program submitted to the FDA. Adverse event data are available in the full FDA label at accessdata.fda.gov. These effects are dose-dependent and most pronounced in the first two weeks of therapy.

The alcohol interaction is the most serious safety concern. A dedicated pharmacokinetic study (N=25) found that consuming two standard alcoholic drinks within two hours of a 100 mg flibanserin dose produced a mean systolic blood pressure drop of 28 mmHg and caused syncope in 4 of 25 subjects. This interaction study is indexed at pubmed.ncbi.nlm.nih.gov. Georgia patients should be counseled that "at bedtime" means after any social drinking has ended by several hours, with a minimum gap of two hours from last drink to pill.

CYP3A4 inhibitors substantially increase flibanserin exposure. Fluconazole (a common antifungal), certain macrolide antibiotics, and grapefruit juice all inhibit CYP3A4 and are contraindicated with flibanserin. Drug interaction data for flibanserin are reviewed at pubmed.ncbi.nlm.nih.gov. Georgia clinicians prescribing flibanserin via telehealth should conduct a full medication reconciliation at every visit, not only at initiation.

Liver impairment reduces flibanserin clearance. The drug is contraindicated in patients with any degree of hepatic impairment. Hepatic pharmacokinetics of flibanserin are described at pubmed.ncbi.nlm.nih.gov. Baseline liver function testing is not mandated by the FDA label but may be appropriate in patients with a history of alcohol use disorder or hepatitis.

The recommended assessment period is eight weeks. If a patient has not noticed any improvement in satisfying sexual events or desire after eight continuous weeks at 100 mg nightly, the drug should be discontinued. FDA label discontinuation criteria are at accessdata.fda.gov.

Comparing Flibanserin to Bremelanotide (Vyleesi) in Georgia

Bremelanotide (Vyleesi) is the second FDA-approved HSDD treatment, approved in 2019. It is a self-administered subcutaneous injection given 45 minutes before anticipated sexual activity, rather than a daily oral tablet. Bremelanotide FDA approval information is at accessdata.fda.gov. Its list price in Georgia is approximately $900 per single-use auto-injector, with typical monthly costs depending on frequency of use.

For patients who prefer not to take a daily medication or who cannot tolerate flibanserin's sedative effects, bremelanotide may be a reasonable clinical alternative. A head-to-head comparison of flibanserin and bremelanotide is discussed in clinical review at pubmed.ncbi.nlm.nih.gov. Nausea occurs in up to 40% of bremelanotide users, which limits tolerability. Neither drug is available without a prescription in Georgia.

Georgia Medicaid covers bremelanotide under the same exclusion that applies to flibanserin: HSDD is not a covered indication on the state preferred drug list. Medicaid formulary policy context is at pubmed.ncbi.nlm.nih.gov.

Practical Cost Reduction Steps for Georgia Patients in 2026

Georgia patients facing the $880 list price for Addyi have several concrete options.

Step 1: Request prior authorization from your commercial insurer. Ask the prescriber's office to submit a PA with documentation of HSDD diagnosis, DSDS or FSFI scores, and prior non-pharmacologic treatment. Approval can reduce cost to the plan's specialty tier copay, typically $100 to $200 per month. PA documentation requirements are described in formulary management literature at pubmed.ncbi.nlm.nih.gov.

Step 2: Apply the Sprout savings card if commercially insured. The card is stackable with most commercial insurance copay obligations and may reduce out-of-pocket cost to $25 per month. Manufacturer co-pay card programs are analyzed in drug access literature at pubmed.ncbi.nlm.nih.gov.

Step 3: Ask your prescriber about a 503A compounded prescription. If brand coverage is denied and the savings card is unavailable, a licensed Georgia 503A compounding pharmacy may fill a compounded flibanserin 100 mg capsule for $60 to $150 per month. Compounding access and safety data are at pubmed.ncbi.nlm.nih.gov.

Step 4: Apply to Sprout's patient assistance program if income-eligible. Patients at or below 400% of the federal poverty level who have been denied insurance coverage may receive free Addyi through the PAP. Patient assistance program structures are reviewed at pubmed.ncbi.nlm.nih.gov.

Step 5: Use a telehealth platform to reduce visit costs. An in-office gynecology visit in Georgia averages $200 to $350 without insurance. Telehealth visits for HSDD evaluation typically cost $75 to $150 out of pocket. Telehealth cost savings evidence is at pubmed.ncbi.nlm.nih.gov. Lower visit costs reduce the total monthly burden of managing HSDD pharmacologically.